Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will deliver a corporate presentation on Monday, January 13, 2025, at 10:30 a.m. PT.
The presentation will be accessible via live webcast through the company's investor relations website under the 'Events & Presentations' section. A replay of the presentation will remain available on the website for a minimum of 14 days following the conference.
Revolution Medicines (RVMD), un'azienda oncologica in fase clinica focalizzata sullo sviluppo di terapie mirate per i tumori dipendenti da RAS, ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference. Il CEO e presidente dell'azienda, Mark A. Goldsmith, M.D., Ph.D., terrà una presentazione aziendale lunedì 13 gennaio 2025, alle 10:30 a.m. PT.
La presentazione sarà accessibile tramite webcast live attraverso il sito web delle relazioni con gli investitori dell'azienda nella sezione 'Eventi e Presentazioni'. Una registrazione della presentazione sarà disponibile sul sito per un minimo di 14 giorni dopo la conferenza.
Revolution Medicines (RVMD), una empresa oncológica en etapa clínica enfocada en desarrollar terapias dirigidas para cánceres adictos a RAS, ha anunciado su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan. El CEO y presidente de la compañía, Mark A. Goldsmith, M.D., Ph.D., ofrecerá una presentación corporativa el lunes 13 de enero de 2025, a las 10:30 a.m. PT.
La presentación estará disponible a través de una transmisión en vivo por el sitio web de relaciones con inversores de la compañía en la sección 'Eventos y Presentaciones'. Una reproducción de la presentación permanecerá disponible en el sitio durante un mínimo de 14 días después de la conferencia.
Revolution Medicines (RVMD), 표적 치료 개발에 중점을 둔 임상 단계의 암 기업이 RAS 의존 암을 대상으로 하여 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO이자 회장인 Mark A. Goldsmith, M.D., Ph.D.가 2025년 1월 13일 월요일, 오전 10:30 PT에 기업 프레젠테이션을 진행할 예정입니다.
프레젠테이션은 회사의 투자자 관계 웹사이트의 '이벤트 및 프레젠테이션' 섹션을 통해 라이브 웹캐스트로 액세스할 수 있습니다. 회의 이후 최소 14일 동안 웹사이트에서 프레젠테이션의 재생 시청이 가능합니다.
Revolution Medicines (RVMD), une entreprise d'oncologie en phase clinique axée sur le développement de thérapies ciblées pour les cancers dépendants de RAS, a annoncé sa participation à la 43e Conférence Annuelle de Santé J.P. Morgan. Le PDG et président de la société, Mark A. Goldsmith, M.D., Ph.D., présentera une présentation d'entreprise le lundi 13 janvier 2025, à 10h30 PT.
La présentation sera accessible en direct via un webcast sur le site web des relations avec les investisseurs de l'entreprise, dans la section 'Événements et Présentations'. Un replay de la présentation sera disponible sur le site pendant un minimum de 14 jours suivant la conférence.
Revolution Medicines (RVMD), ein klinisch tätiges Onkologieunternehmen, das sich auf die Entwicklung gezielter Therapien für RAS-abhängige Krebsarten konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference angekündigt. Der CEO und Vorsitzende des Unternehmens, Mark A. Goldsmith, M.D., Ph.D., wird am Montag, den 13. Januar 2025, um 10:30 Uhr PT eine Unternehmenspräsentation halten.
Die Präsentation wird über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens im Abschnitt 'Veranstaltungen & Präsentationen' zugänglich sein. Eine Wiederholung der Präsentation wird für mindestens 14 Tage nach der Konferenz auf der Website verfügbar bleiben.
- None.
- None.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT.
To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
When is Revolution Medicines (RVMD) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Revolution Medicines' (RVMD) J.P. Morgan Healthcare Conference presentation?
How long will the replay of RVMD's J.P. Morgan Healthcare Conference presentation be available?
What type of cancer treatments is Revolution Medicines (RVMD) developing?
